Peptide for treating ocular diseases and composition for treating ocular diseases comprising same
A pharmaceutical composition for preventing or treating ophthalmopathy is described. More particularly, a composition comprising a peptide derived from telomerase and being effective in treating and preventing ophthalmopathy is described. The peptide derived from telomerase, a peptide having a sequence 80% identical to the sequence thereof, or a peptide as a fragment thereof is superiorly effective in treating ophthalmopathy.
1. A method of treating ophthalmopathy, comprising: administering to a subject in need thereof an effective amount of an isolated peptide consisting of the amino acid sequence of SEQ ID NO: 1 for treatment of ophthalmopathy.
2. The method of claim 1 , wherein the ophthalmopathy comprises one or more selected from the group consisting of diabetic retinopathy, retinopathy of prematurity, corneal graft rejection, neovascular glaucoma, rubeosis, proliferative retinopathy, dry eye syndrome, and macular degeneration.
3. The method of claim 1 , wherein the ophthalmopathy is age-related ophthalmopathy or is caused by choroidal neovascularization.
4. The method of claim 1 , wherein the peptide is administered at a daily dose of 10 ng/kg to 10 mg/kg.
5. The method of claim 1 , wherein the peptide is administered 1 to 3 times a day.
6. A kit for treating ophthalmopathy, comprising a composition which comprises the isolated peptide of SEQ ID NO: 1; and a manual.
7. A method of treating ophthalmopathy, comprising: administering to a subject in need thereof a composition comprising an effective amount of an isolated peptide consisting of the amino acid sequence of SEQ ID NO: 1 for treatment of ophthalmopathy.
8. The method of claim 7 , wherein the ophthalmopathy comprises one or more selected from the group consisting of diabetic retinopathy, retinopathy of prematurity, corneal graft rejection, neovascular glaucoma, rubeosis, proliferative retinopathy, dry eye syndrome, and macular degeneration.
9. The method of claim 7 , wherein the ophthalmopathy is age-related ophthalmopathy.
10. The method of claim 7 , wherein the ophthalmopathy is caused by choroidal neovascularization.
11. The method of claim 7 , wherein the composition comprises 0.01 g/L to 1 kg/L of the peptide.
12. The method of claim 7 , wherein the peptide is administered at a daily dose of 10 ng/kg to 10 mg/kg.
13. The method of claim 7 , wherein the peptide is administered 1 to 3 times a day.
14. The method of claim 7 , wherein the composition is a pharmaceutical composition further comprising a pharmaceutically acceptable excipient and an additive.
15. The method of claim 7 , wherein the composition is a food composition.